{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:24:24Z","timestamp":1784838264943,"version":"3.55.0"},"reference-count":80,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T00:00:00Z","timestamp":1447804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0143333","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T18:57:07Z","timestamp":1447873027000},"page":"e0143333","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells"],"prefix":"10.1371","volume":"10","author":[{"given":"Dario","family":"Presutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Cardinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Papoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Lalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Samperna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fustaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovina","family":"Ruberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1432-0436.2007.00238.x","article-title":"The epidermal growth factor receptor: from development to tumorigenesis","volume":"75","author":"M Sibilia","year":"2007","journal-title":"Differentiation"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"MA Lemmon","year":"2010","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"J Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"L Ding","year":"2008","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"M Imielinski","year":"2012","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"R Govindan","year":"2012","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"D Jackman","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"W Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1038\/sj.onc.1210383","article-title":"EGFR kinase domain mutations\u2014functional impact and relevance for lung cancer therapy","volume":"26","author":"D Irmer","year":"2007","journal-title":"Oncogene"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"GJ Riely","year":"2006","journal-title":"Clin Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"TJ Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"JG Paez","year":"2004","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from &quot;never smokers&quot; and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"W Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"F Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-04-1981","article-title":"Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer","volume":"11","author":"TY Chou","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","article-title":"Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib","volume":"23","author":"SW Han","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2005.00.992","article-title":"Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence","volume":"23","author":"T Mitsudomi","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib","volume":"352","author":"S Kobayashi","year":"2008","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"CH Yun","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"DR Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-07-2248","article-title":"Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"14","author":"JA Engelman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Z Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"J Bean","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"JA Engelman","year":"2007","journal-title":"Science"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature09870","article-title":"FAS and NF-\u03baB signalling modulate dependence of lung cancers on mutant EGFR","volume":"471","author":"TG Bivona","year":"2011","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1078-0432.CCR-12-3232","article-title":"Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT","volume":"19","author":"DS Neel","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1158\/0008-5472.CAN-12-4136","article-title":"Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells","volume":"73","author":"K Shien","year":"2013","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.1158\/0008-5472.CAN-05-1058","article-title":"Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition","volume":"65","author":"S Thomson","year":"2005","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tcb.2009.07.002","article-title":"Crosstalk in Met receptor oncogenesis","volume":"19","author":"AZ Lai","year":"2009","journal-title":"Trends Cell Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"L Trusolino","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdn635","article-title":"MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients","volume":"20","author":"F Cappuzzo","year":"2009","journal-title":"Ann Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"AB Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s11864-014-0313-5","article-title":"C-MET inhibitors in the treatment of lung cancer","volume":"15","author":"J Go\u017adzik-Spychalska","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrclinonc.2012.71","article-title":"MET: a promising anticancer therapeutic target","volume":"9","author":"S Peters","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"E Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"T Mosmann","year":"1983","journal-title":"J Immunol Meth"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-1759(89)90397-9","article-title":"Re-examination and further development of a precise and rapid dye method for measuring cell growth\/cell kill","volume":"119","author":"MB Hansen","year":"1989","journal-title":"J Immunol Methods"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"NA Franken","year":"2006","journal-title":"Nat Protoc"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"TC Chou","year":"2010","journal-title":"Cancer Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1535-7163.MCT-13-0170","article-title":"Axl mediates acquired resistance of head and neck cancer cells to the Epidermal Growth Factor Receptor inhibitor erlotinib","author":"KM Giles","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"AJ Barker","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"ref44","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"JD Moyer","year":"1997","journal-title":"Cancer Research"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-08-4055","article-title":"PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR","volume":"69","author":"ML Sos","year":"2009","journal-title":"Cancer Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"MA Jordan","year":"2004","journal-title":"Nature reviews Cancer"},{"key":"ref47","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"F1 Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.bjc.6602603","article-title":"ZD6474: a novel inhibitor of VEGFR and EGFR tyrosine kinase activity","volume":"92","author":"AJ Ryan","year":"2005","journal-title":"Br J Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","article-title":"Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions","volume":"14","author":"A Morabito","year":"2009","journal-title":"Oncologist"},{"key":"ref50","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo","volume":"1","author":"DW Rusnak","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"BJ Druker","year":"1996","journal-title":"Nat Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"FJ Giles","year":"2009","journal-title":"Leukemia"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"DA Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"AO Walter","year":"2013","journal-title":"Cancer Discov"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"T Kosaka","year":"2004","journal-title":"Cancer Res"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Med"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"H Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1158\/1078-0432.CCR-05-1981","article-title":"Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features","volume":"12","author":"IY Tam","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/bjc.2014.210","article-title":"Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts","volume":"110","author":"S Li","year":"2014","journal-title":"Br J Cancer"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/bjc.2014.401","article-title":"Coexistence of <italic>KRAS<\/italic> mutation with mutant but not wild-type <italic>EGFR<\/italic> predicts response to tyrosine-kinase inhibitors in human lung cancer","volume":"111","author":"A Choughule","year":"2014","journal-title":"British Journal of Cancer"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"MA Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/sj.bjc.6600286","article-title":"Evaluation of HER-2\/neu gene amplification and protein expression in non-small cell lung carcinomas","volume":"86","author":"FR Hirsch","year":"2002","journal-title":"Br J Cancer"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.semcdb.2010.08.007","article-title":"The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics","volume":"21","author":"DN Amin","year":"2010","journal-title":"Semin Cell Dev Biol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/adt.2013.540","article-title":"High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors","volume":"12","author":"H Tang","year":"2014","journal-title":"Assay Drug Dev Technol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1158\/0008-5472.CAN-13-1103","article-title":"MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to to EGFR kinase inhibitors due to MET or AXL activation","volume":"74","author":"JK Rho","year":"2014","journal-title":"Cancer Research"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/mt.2012.163","article-title":"Targeting Axl with an high-affinity inhibitory aptamer","volume":"20","author":"L Cerchia","year":"2012","journal-title":"Mol Ther"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"10146","DOI":"10.18632\/oncotarget.3380","article-title":"Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer","volume":"6","author":"SY Bae","year":"2015","journal-title":"Oncotarget"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer","volume":"70","author":"SJ1 Holland","year":"2010","journal-title":"Cancer Res"},{"key":"ref70","first-page":"5462","article-title":"A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase","volume":"63","author":"M Sattler","year":"2003","journal-title":"Cancer Res"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/2193-1801-3-554","article-title":"Differential regulation of c-Met signaling pathways for synovial cell function","volume":"3","author":"S Shibasaki","year":"2014","journal-title":"SpringerPlus"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"e59708","DOI":"10.1371\/journal.pone.0059708","article-title":"Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib","volume":"8","author":"G Chen","year":"2013","journal-title":"PLoS One"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"er11","DOI":"10.1126\/scisignal.2000643","article-title":"Only a subset of Met-activated pathways are required to sustain oncogene addiction","volume":"2","author":"A Bertotti","year":"2009","journal-title":"Sci Signal"},{"key":"ref74","first-page":"7345","article-title":"A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo","volume":"63","author":"JG Christensen","year":"2003","journal-title":"Cancer Res"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","article-title":"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer","volume":"55","author":"JJ Cui","year":"2012","journal-title":"J Med Chem"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/bi900438w","article-title":"Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors","volume":"48","author":"SL Timofeevski","year":"2009","journal-title":"Biochemistry"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1535-7163.MCT-11-0839","article-title":"Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor","volume":"11","author":"HY Zou","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1074\/jbc.275.12.8806","article-title":"Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells","volume":"275","author":"M Jo","year":"2000","journal-title":"J Biol Chem"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-2187-5-8","article-title":"EGFR\/Met association regulates EGFR TKI resistance in breast cancer","volume":"5","author":"KL Mueller","year":"2010","journal-title":"J Mol Signal"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/bjc.2011.322","article-title":"Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification","volume":"105","author":"J Tanizaki","year":"2011","journal-title":"British J of Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0143333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T02:00:04Z","timestamp":1540346404000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0143333"}},"subtitle":[],"editor":[{"given":"Jung Weon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,18]]},"references-count":80,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0143333","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,18]]}}}